Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies

This publication has 108 references indexed in Scilit:

• Clinical Significance of sIL-2R Levels in B-Cell Lymphomas
  PLOS ONE, 2013
• CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
  Experimental Hematology & Oncology, 2012
• Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
  Journal of Clinical Oncology, 2012
• Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
  Cancer Cell, 2012
• Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
  Cancer Science, 2012
• Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
  Leukemia, 2011
• Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
  Clinical Cancer Research, 2008
• Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
  Blood, 2008
• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
  Nature Biotechnology, 2008
• CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms
  Clinical Cancer Research, 2007